Published July 23, 2026
To understand why a July 2026 appeals court decision is such a big deal for families pursuing Tylenol autism claims, it helps to go back to where the litigation nearly died: a December 2024 ruling by U.S. District Judge Denise Cote in the Southern District of New York. Judge Cote, overseeing the consolidated federal multidistrict litigation, ruled that the plaintiffs' scientific experts had relied on methodology that wasn't reliable enough to be presented to a jury. Without that expert testimony, more than 500 lawsuits alleging prenatal acetaminophen use contributed to a child's autism or ADHD were effectively dismissed.
The ruling was a significant win for Kenvue, the Tylenol manufacturer, which has consistently maintained that no causal link between the drug and autism has been scientifically established. For families who had already filed claims, the dismissal meant their cases stalled without a resolution on the merits — the science behind their claims, rather than being heard by a jury, was found inadmissible as a matter of law.
Plaintiffs appealed to the Second Circuit, and the case sat in that appellate posture for over a year. Oral arguments were held in November 2025, with the litigation effectively frozen in the meantime — no bellwether trials, no settlement talks, and no forward movement for the hundreds of families whose cases had been tossed. During that stretch, state court cases (which aren't bound by federal rulings) continued to be filed independently around the country, giving families an alternative path even while the federal appeal was pending.
That long pause ended on July 13, 2026, when the Second Circuit reversed Judge Cote's exclusion of three key experts and sent the cases back to her for further proceedings. The reversal doesn't guarantee any particular outcome — Kenvue can still challenge the experts again, and individual plaintiffs will still need to prove their child's condition was caused by acetaminophen exposure — but it reopens a door that had been closed since 2024.
This back-and-forth is a reminder that mass tort litigation rarely moves in a straight line, and that a dismissal at one stage doesn't necessarily mean a claim has no future. See Atumio's Tylenol autism lawsuit page for a free eligibility review, or start your case review directly.